ANIX - Anixa Biosciences Cleveland Clinic in ovarian cancer vaccine pact

Anixa Biosciences ([[ANIX]] +4.5%) has entered into a license agreement with Cleveland Clinic for exclusive, world-wide rights to an ovarian cancer vaccine technology. The development-stage vaccine targets the extracellular domain of anti-mullerian hormone receptor 2 (AMHR2-ED), that appears in many types of ovarian cancer.Anixa and Cleveland Clinic are already collaborating on a preventative breast cancer vaccine, and human trials are expected to commence in early next year.

For further details see:

Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact